Provider Briefing: Ella Availability in 2026

If your patients are reporting difficulty filling Ella (Ulipristal Acetate 30 mg) prescriptions, they're not imagining it. Despite the absence of an official FDA shortage listing, Ella remains one of the most consistently hard-to-find medications at retail pharmacies across the United States.

This article provides a clinical overview of the current Ella availability landscape, prescribing considerations, cost and access barriers, and practical tools to help your patients get the medication they need.

Timeline: How We Got Here

Ella (Ulipristal Acetate) received FDA approval in August 2010 as the first selective progesterone receptor modulator indicated for emergency contraception. It was launched in U.S. pharmacies in December 2010 by Laboratoire HRA Pharma, which was subsequently acquired by Perrigo Company in 2022 for approximately $2.1 billion.

Key milestones affecting availability:

• 2010: FDA approval and U.S. launch. From the outset, pharmacy stocking was inconsistent due to the prescription-only requirement and intermittent demand patterns.
• 2020-2021: COVID-19 pandemic shifted patient behavior toward telehealth, creating new access pathways but also disrupting traditional pharmacy supply chains.
• June 2022: The Dobbs v. Jackson decision triggered an unprecedented surge in demand for emergency contraception. Ella supplies were rapidly depleted at pharmacies that did stock it, and patients in states with new abortion restrictions sought to stockpile the medication.
• 2023-2025: Demand normalized somewhat, but the stocking problem persisted. No generic entrants emerged, and the medication remained absent from many pharmacy formularies.
• 2026: The situation remains largely unchanged. Ella is produced in adequate quantities by the manufacturer, but retail availability continues to be inconsistent.

Prescribing Implications

When prescribing Ella, providers should be aware of several clinical and practical considerations:

Clinical Considerations

• Efficacy window: Ella is effective for up to 120 hours (5 days) after unprotected intercourse, maintaining consistent efficacy throughout this window — a key advantage over Levonorgestrel-based options, which decline in effectiveness after 72 hours.
• Interaction with hormonal contraceptives: Ella and progestin-containing contraceptives bind to the same receptor. Concurrent use may reduce the effectiveness of both. Advise patients to use barrier methods until the next menstrual period before resuming hormonal contraception.
• CYP3A4 interactions: CYP3A4 inducers (Rifampin, Phenytoin, Carbamazepine, St. John's Wort) may reduce Ella's efficacy. CYP3A4 inhibitors (Ketoconazole) increase Ulipristal exposure significantly (AUC increased ~5.9-fold).
• Weight considerations: While data is limited, Ella appears to maintain effectiveness across a broader weight range than Levonorgestrel-based options.
• Contraindications: Known or suspected pregnancy. Ella is not intended for pregnancy termination.

Practical Prescribing Tips

• Prescribe proactively: Consider offering advance prescriptions for Ella during routine reproductive health visits. Patients can fill the prescription and keep it on hand.
• Verify pharmacy stock before sending: Before e-prescribing Ella to a pharmacy, recommend that patients call ahead to confirm availability — or use Medfinder for Providers to check stock.
• Include the generic name: Write "Ulipristal Acetate 30 mg" alongside the brand name to help pharmacists identify the product in their ordering systems.
• Consider telehealth referral: For patients who cannot find Ella locally, telehealth platforms (Nurx, Wisp, GoodRx Care) can prescribe and ship directly.

Current Availability Picture

The core issue with Ella access is not a manufacturing shortage but a last-mile distribution problem:

• Perrigo continues to manufacture Ella in adequate quantities
• Ella is not listed on the FDA Drug Shortage Database
• Many retail pharmacies (both chain and independent) do not routinely stock it
• Wholesaler availability is inconsistent — some distributors carry it intermittently
• No generic version exists, limiting supply to a single manufacturer

Geographically, availability tends to be better in urban areas and near reproductive health clinics. Rural areas and regions with restrictive reproductive health policies may have fewer stocking pharmacies.

Cost and Access Considerations

Understanding cost barriers helps providers counsel patients effectively:

• Cash price: $40-$90 per tablet at retail pharmacies
• With discount coupons (GoodRx): As low as $39-$43
• Telehealth platforms: ~$45 (Nurx, Wisp) without insurance
• ACA coverage: Most commercial insurance plans must cover Ella at $0 cost-sharing when prescribed
• Medicaid: Coverage varies by state; many state Medicaid programs cover emergency contraception

For patients facing cost barriers, providers can direct them to our guide: How to Save Money on Ella.

Tools and Resources for Providers

Several resources can streamline Ella access for your patients:

Medfinder for Providers

Medfinder offers real-time pharmacy availability data. Use it to direct patients to pharmacies that currently have Ella in stock, eliminating the frustrating pharmacy-to-pharmacy search.

Telehealth Referral Options

When local availability is limited, the following platforms can prescribe and deliver Ella:

• Nurx: Online consultation, $45 for Ella, free ground shipping or $15 overnight
• Wisp: Same-day prescriptions with fast shipping
• GoodRx Care: Online visit with prescription sent to patient's preferred pharmacy
• Planned Parenthood Direct: App-based consultation in many states

Clinical Resources

• ellarx.com: Official prescribing information and patient resources
• ellahcp.com: Healthcare provider-specific information from the manufacturer
• ACOG Practice Bulletin on Emergency Contraception: Current clinical guidelines

For a practical workflow guide, see our article on how to help your patients find Ella in stock.

Looking Ahead

Several developments may impact Ella availability in the coming years:

• Generic competition: No generic Ulipristal Acetate is currently approved in the U.S. If generic entrants emerge, increased supply and lower prices could improve access significantly.
• OTC switch potential: While there is no active effort to make Ella available over the counter, the precedent set by other emergency contraceptives suggests this could be considered in the future.
• Policy changes: Evolving state and federal reproductive health policies will continue to impact both demand and access for emergency contraception.
• Telehealth growth: The continued expansion of telehealth will likely become the primary access pathway for Ella, bypassing traditional pharmacy stocking challenges.

Final Thoughts

Ella remains the most effective emergency contraceptive pill available, but its practical accessibility continues to lag behind its clinical utility. As providers, we can improve patient outcomes by prescribing proactively, verifying pharmacy stock, and connecting patients with tools like Medfinder and telehealth services.

For additional provider resources, see our guides on helping patients find Ella and helping patients save money on Ella.